Optimization Strategy of Carotid Artery Stenosis
Condition(s) studied
Investigational drug(s) / intervention(s)
Carotid revascularization: All patients received carotid revascularization surgery at Peking Union Medical College Hospital.
MRI-PWI: Multi-modal MRI before and after surgery.
CTA: CTA before and after surgery.
PET/MRI: PET/MRI before surgery.
Ultrasound: Ultrasound before and after surgery.
Study summary
The goal of this observational study is to learn about how to utilize multiple evaluation techniques in carotid artery stenosis patients for optimizing assessment of diagnosis and treatment strategy.
The main questions it aims to answer are:
* Identify best strategy that use multi-modal MRI and CT to assess patients' cerebral lesions and perfusion.
* Identify best strategy that use multi-modal MRI, PET-MRI ultrasound and CT to assess components and characters of patients' carotid plaques.
Participants will accept imaging examination before and after surgery. And doctors will collect basic characteristics, imaging results and biological samples of patients for analysis.
Eligibility
Primary outcome measure(s)
- stroke — During hospital stay, usually 7-30 days post operation
perioperative stroke - cardiac infarction — During hospital stay, usually 7-30 days post operation
perioperative cardiac infarction - transient ischemic attack — During hospital stay, usually 7-30 days post operation
perioperative transient ischemic attack - cerebral hyperperfusion syndrome — During hospital stay, usually 7-30 days post operation
perioperative cerebral hyperperfusion syndrome - death — During hospital stay, usually 7-30 days post operation
perioperative death
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| vascular surgery department of PUMCH | Beijing | Beijing Municipality | Recruiting |
More Peking Union Medical College Hospital trials in China
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT05629000 on ClinicalTrials.gov ↗ ← All trials in China